19% og 68% og nedsætter AUC for den 14- hydroxy- aktive metabolit med over 95%.
APTIVUS, co-administered with low dose ritonavir, increases the AUC and Cmin of clarithromycin by 19% and 68%, respectively, and decreases the AUC of the 14-hydroxy active metabolite by over 95%.